New hope for lung scarring: experimental drug zampilimab enters Mid-Stage trial
NCT ID NCT07516951
First seen Apr 23, 2026 · Last updated May 15, 2026 · Updated 3 times
Summary
This study tests an experimental drug called zampilimab in 240 adults with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and makes breathing hard. Participants will receive one of two doses of the drug or a placebo for 24 weeks, with an optional 24-week extension. The main goal is to see if the drug improves lung function.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.